Tubercular Drug Delivery Systems: Advances in Treatment of Infectious Diseases

ISBN-13: 9783031140990 / Angielski / Twarda / 2023 / 337 str.

Ranjita Shegokar; Yashwant V. Pathak

Opis

The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis.  It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy.  A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research.
.

Spis treści

1. Global health and Tuberculosis past, present and Future.
2. Tuberculosis: cellular understanding of disease
3. Metal nanoparticles in TB
4. TB: current treatment options
5. Polymeric nanoparticles in TB
6. Solid lipid nanoparticles in TB
7. Dendrimers in TB
8. Liposomes in TB
9. Micro, nano emulsions in TB
10. Nano suspension in TB
11. Alginate, gelatin nanoparticles in TB
12. Niosome in TB
13. Surface modified drug delivery systems in TB
14. Clinical trials in TB
15. Herbal platforms in TB​

O autorze

Dr. Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Since last several years she is working with various multinational pharmaceutical companies at technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer, CapnoPharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and active targeting. Besides that, she edited many trending books on nanoparticles and their aspects. For her research, she received many prestigious national and international awards, among them the recent one is German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions for targeting various diseases and the role of excipients in developing the same.



Dr. Yashwant Pathak completed his Ph.D. in Pharmaceutical Technology from India and EMBA and MS Conflict Management from Sullivan University, USA. He is Associate Dean for Faculty Affairs College of Pharmacy, University of South Florida. Tampa, Florida. With extensive experience in academia and industry, he has over 150 research publications, abstracts, chapters and reviews, 7 books in Nanotechnology and drug delivery systems, 6 in Nutraceuticals and several books in cultural studies. His areas of research include drug delivery systems, nanotechnology applications for pharmaceutical and Nutraceuticals. He has traveled extensively over 80 countries to network scientific experts and is actively involved with many Pharmacy colleges in different countries.

Blurb

The disability-adjusted life year (DALY) is a generic measure of health effect that can

be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year

(QALY). Infectious diseases are one of the major to cause significant losses of DALY and

QALY. Human infectious diseases are disorders that are triggered by the microorganisms

such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious

and create a public health menace. There are several reasons why infectious diseases

are deadly diseases, and one of the primary reasons is the drug resistance developed

over time. Drug resistance-associated mutations are linked to increasing drug efflux,

modifications of the drugs, or their targets. Every year, new drugs are being approved by

FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly

persist as permanent and main threats to humanity now and in the future, primarily

due to increased longevity that almost always comes at a cost of impaired immunity.

A total of four books are covered under the series of Infectious diseases.

• Malarial drug delivery systems

• Tubercular drug delivery systems

• Viral drug delivery systems

• Infectious disease drug delivery systems

The theme of the second book is Tuberculosis (TB). This book addresses the recent

trends in drug delivery for treating TB using new formulation technologies, and the

mechanism how it can prevent or delay the drug resistance. It covers current drug therapy

and new drug targeting approaches focusing on innovative trend-defining technologies

and drug delivery platforms. It is essential to understand the relationship between host

pathogens for better treatment. Various novel and nano-formulations using promising

technologies are being explored to deliver TB drugs via different administration routes

at right pathological site. This book addresses the gap between new and old treatment

TB modalities and how they are superior in pharmacological performance when tested

in in-vitro and in-vivo.

Audiences from a broad range of groups, from researchers, academicians, and public

health bodies to regulatory experts, can benefit from the compiled information to learn

more about patient needs and current research advances in the field of TB research.